Brokerages expect Mediwound Ltd (NASDAQ:MDWD) to announce $1.10 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Mediwound’s earnings, with the lowest sales estimate coming in at $1.00 million and the highest estimate coming in at $1.20 million. Mediwound reported sales of $1.03 million in the same quarter last year, which indicates a positive year over year growth rate of 6.8%. The company is scheduled to announce its next quarterly earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that Mediwound will report full-year sales of $10.32 million for the current fiscal year, with estimates ranging from $7.80 million to $14.20 million. For the next financial year, analysts anticipate that the company will post sales of $19.05 million, with estimates ranging from $13.80 million to $26.70 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Mediwound.
Mediwound (NASDAQ:MDWD) last issued its quarterly earnings data on Tuesday, May 21st. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.01). The business had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.60 million. Mediwound had a negative return on equity of 383.19% and a negative net margin of 18.43%.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP bought a new stake in shares of Mediwound during the first quarter valued at approximately $93,000. Delek Group Ltd. bought a new stake in shares of Mediwound during the first quarter valued at approximately $141,000. Oppenheimer & Co. Inc. boosted its position in shares of Mediwound by 6.5% during the first quarter. Oppenheimer & Co. Inc. now owns 32,800 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 2,000 shares in the last quarter. Deutsche Bank AG boosted its position in shares of Mediwound by 73.5% during the fourth quarter. Deutsche Bank AG now owns 39,740 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 16,840 shares in the last quarter. Finally, Menta Capital LLC boosted its position in shares of Mediwound by 200.2% during the first quarter. Menta Capital LLC now owns 44,514 shares of the biopharmaceutical company’s stock valued at $223,000 after purchasing an additional 29,686 shares in the last quarter. Institutional investors own 30.78% of the company’s stock.
Shares of MDWD stock traded down $0.02 during trading hours on Friday, reaching $3.20. The company’s stock had a trading volume of 32,947 shares, compared to its average volume of 63,955. The company has a market capitalization of $87.52 million, a PE ratio of -6.53 and a beta of 0.57. Mediwound has a one year low of $3.00 and a one year high of $6.75. The business’s fifty day moving average is $3.67. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.99 and a quick ratio of 3.79.
Mediwound Company Profile
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Featured Story: What are the risks of holding treasury bonds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.